(S1 (S (S (NP (NN Hyperfibrinogenemia)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (JJ lymphatic) (ADJP (CONJP (RB as) (RB well) (IN as)) (ADJP (JJ hematogenous))) (NN metastasis)) (CC and) (NP (JJ worse) (JJ clinical) (NN outcome))) (PP (IN in) (NP (NN T2) (JJ gastric) (NN cancer)))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (S (NP (NP (JJ Abnormal) (NN hemostasis)) (PP (IN in) (NP (NN cancer) (NNS patients)))) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN described))))) (, ,) (S (ADVP (RB however)) (NP (NP (DT the) (NN correlation)) (PP (IN between) (NP (NP (DT the) (NN plasma) (NN fibrinogen) (NN level)) (CC and) (NP (NP (NN cancer) (NN metastasis)) (CC and) (NP (NN prognosis)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (DT a) (JJ large-scale) (JJ clinical) (NN study)))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (JJ Preoperative) (NN plasma) (NN fibrinogen) (NNS levels)) (VP (VBD were) (ADVP (RB retrospectively)) (VP (VBN examined) (PP (IN in) (NP (NP (CD 405) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (NN surgery)) (PP (IN for) (NP (JJ advanced) (JJ gastric) (NN cancer)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NN fibrinogen) (NNS levels))) (PP (IN with) (NP (NP (JJ clinical/pathological) (NNS findings)) (CC and) (NP (JJ clinical) (NN outcome))))) (VP (VBD was) (VP (VBN evaluated)))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN between) (NP (NP (NP (NN plasma) (NN fibrinogen) (NNS levels)) (CC and) (NP (NP (DT the) (NN depth)) (PP (IN of) (NP (NN invasion))))) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (NP (NP (NN Hyperfibrinogenemia)) (PRN (-LRB- -LRB-) (NP (NN >) (CD 310) (NN mg/dl)) (-RRB- -RRB-))) (VP (VBD was) (ADVP (RB independently)) (VP (VBN associated) (PP (IN with) (NP (NP (NN lymph) (NN node)) (PRN (-LRB- -LRB-) (NP (NNS Odds) (NN Ratio)) (: ;) (NP (CD 2.342)) (, ,) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.0032)))) (-RRB- -RRB-)) (CC and) (NN liver) (PRN (-LRB- -LRB-) (NP (NP (NNS Odds)) (NP (NN Ratio)) (: ;) (NP (CD 2.933)) (, ,) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.0147))))) (-RRB- -RRB-)) (NN metastasis))) (, ,) (PP (RB not) (IN with) (NP (NP (JJ peritoneal) (NN metastasis)) (PP (IN in) (NP (DT this) (NN series))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNS hyperfibrinogenemia)))) (VP (VBD showed) (NP (NP (JJ worse) (JJ clinical) (NN outcome)) (PP (IN in) (NP (NN T2) (JJ gastric) (NN cancer)))))) (, ,) (S (ADVP (RB however)) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN correlation)) (PP (IN of) (NP (NN plasma) (NN fibrinogen) (NN level))) (PP (IN with) (NP (NP (NN prognosis)) (PP (IN in) (NP (NN T3/T4) (JJ gastric) (NN cancer)))))))) (. .)))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (PRP$ Our) (NNS results)) (MD might) (VP (VBP support) (NP (DT the) (NN idea) (SBAR (IN that) (S (NP (NN hyperfibrinogenemia)) (VP (MD can) (VP (VB augment) (NP (NP (ADJP (ADJP (JJ lymphatic)) (CC and) (ADJP (JJ hematogeneous))) (NN metastasis)) (PP (IN of) (NP (JJ advanced) (JJ gastric) (NN cancer))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (JJ major) (NN determinant)) (PP (IN of) (NP (NP (DT the) (NN prognosis)) (PP (IN in) (NP (NN T2) (JJ gastric) (NN cancer))))))))))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (NP (DT the) (NN situation)) (PP (IN without) (NP (NN peritoneal) (NN involvement))))) (, ,) (NP (NN hyperfibrinogenemia)) (VP (VBZ is) (NP (NP (DT a) (JJ useful) (NN biomarker)) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (JJ possible) (NN metastasis) (CC and) (JJ worse) (JJ clinical) (NN outcome)) (PP (IN in) (NP (NN T2) (JJ gastric) (NN cancer)))))))))) (. .)))
